Atara Biotherapeutics, Inc. Balance Sheet
ATRA|2 years of annual SEC 10-K data (FY2024-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
Atara Biotherapeutics, Inc. had $20M in total assets with negative shareholders' equity of $39M as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -73.54 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Cash & Equivalents | $8.5M | $25.0M |
| Accounts Receivable | $1.3M | $1.5M |
| Inventory | $0 | $10.7M |
| Current Assets | $12.2M | $64.9M |
| PP&E (Net) | $73.0K | $1.3M |
| Total Assets | $20.2M | $109.1M |
| Current Liabilities | $14.9M | $134.6M |
| Shareholders' Equity | -$38.5M | -$99.2M |